Financial Contrast: Seaport Therapeutics (SPTX) vs. Its Rivals

Seaport Therapeutics (NASDAQ:SPTX) is one of 907 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Seaport Therapeutics to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, earnings, dividends, profitability and valuation.

Profitability

This table compares Seaport Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Seaport Therapeutics Competitors	-2,303.79%	-221.76%	-17.81%

Institutional and Insider Ownership

32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Seaport Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2	3	5	0	2.30
Seaport Therapeutics Competitors	7693	13651	25519	992	2.41

Seaport Therapeutics presently has a consensus target price of $38.40, suggesting a potential upside of 59.47%. As a group, “Pharmaceuticals” companies have a potential upside of 27.87%. Given Seaport Therapeutics’ higher probable upside, analysts clearly believe Seaport Therapeutics is more favorable than its competitors.

Earnings & Valuation

This table compares Seaport Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seaport Therapeutics	N/A	-$74.88 million	-1.99
Seaport Therapeutics Competitors	$3.50 billion	$3.13 billion	541.39

Seaport Therapeutics’ competitors have higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Seaport Therapeutics competitors beat Seaport Therapeutics on 8 of the 12 factors compared.

About Seaport Therapeutics

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.